Anti-inflammatory therapy in cystic fibrosis (Q44690839)

5 December 2017

1 reference

title

[Anti-inflammatory therapy in cystic fibrosis] (English)

1 reference

5 December 2017

0 references

Derelle J

1

1 reference

5 December 2017

publication date

1 September 2003

1 reference

5 December 2017

published in

Archives de Pediatrie

1 reference

5 December 2017

volume

10 Suppl 2

1 reference

5 December 2017

page(s)

370s-375s

1 reference

Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

The Role of Nuclear Factor- κ B in Cytokine Gene Regulation

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Fluticasone propionate inhibits lipopolysaccharide-induced proinflammatory response in human cystic fibrosis airway grafts

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Inflammatory cytokines in cystic fibrosis lungs

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Glucocorticoid treatment reduces exhaled nitric oxide in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influenc

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Controlled Trial of Inhaled Budesonide in Patients with Cystic Fibrosis and Chronic BronchopulmonaryPseudomonas aeruginosaInfection

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

International practice patterns by age and severity of lung disease in cystic fibrosis: Data from the epidemiologic registry of cystic fibrosis (ERCF)

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Effect of high-dose ibuprofen in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Aerosol α1 -antitrypsin treatment for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Neutrophil elastase/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Long-term azithromycin may improve lung function in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016/S0929-693X(03)90055-8

7 January 2021

10.1016/S0929-693X(03)90055-8

Identifiers

DOI

1 reference

5 December 2017

1 reference